Pfizer Partners with Nona Biosciences for Heavy Chain-Only Antibody Discovery Platform
核心洞察
Pfizer has entered a non-exclusive license agreement with Nona Biosciences (搜索) to access their proprietary HCAb (搜索) platform for generating fully human heavy chain-only antibodies (搜索) across multiple disease indications.
The collaboration leverages Nona's Harbour Mice® platform, described as the world's first fully human HCAb (搜索) transgenic mouse with clinical validation, offering versatility for diverse therapeutic applications.
Under the agreement terms, Nona will receive upfront payments and be eligible for regulatory, clinical, and commercial milestone payments while potentially collaborating on antibody discovery and development.
Pfizer has secured global rights to Nona Biosciences (搜索)' proprietary heavy chain-only antibody (HCAb (搜索)) platform through a non-exclusive license agreement announced November 19, 2025. The collaboration aims to accelerate preclinical antibody discovery across multiple potential disease indications, leveraging Nona's fully human antibody generation technology.
Strategic Partnership Details
Under the agreement terms, Pfizer gains access to Nona's HCAb (搜索) platform to generate fully human heavy chain-only antibodies (搜索) for therapeutic development. Nona Biosciences (搜索) will receive an upfront payment and remains eligible for regulatory, clinical, and commercial milestone payments throughout the partnership. The companies may also collaborate on antibody discovery, development, and engineering using Nona's advanced B-cell screening technologies and integrated services.
"We are pleased to continue providing support for Pfizer's preclinical antibody discovery," said Dr. Di Hong, Chief Executive Officer of Nona Biosciences (搜索). "By leveraging our fully human HCAbs, we aim to accelerate the discovery and development of transformative therapies for patients worldwide."
Harbour Mice® Platform Technology
The collaboration centers on Nona's Harbour Mice® platform, which generates fully human monoclonal antibodies (搜索) in both classical two light and two heavy chain (H2L2) format and heavy chain-only (HCAb (搜索)) format. The HCAb Harbour Mice® represents the world's first fully human HCAb transgenic mouse with clinical validation, according to the company.
This unique platform offers exceptional versatility for diverse therapeutic applications using fully human VH single-domain antibodies as a plug-and-play system. The technology enables development of bispecific antibodies (搜索), multi-specific antibodies, CAR-T therapies (搜索), antibody-drug conjugates (搜索) (ADCs), mRNA-based therapeutics (搜索), and other advanced modalities.
Integrated Discovery Solutions
Nona Biosciences (搜索) positions itself as providing integrated solutions from "Idea to IND," covering target validation and antibody discovery through preclinical research. The company's integrated antibody and antibody-related discovery services span antigen preparation, animal immunization, single B cell screening, antibody lead generation and engineering, developability assessment, and pharmacological evaluation.
The platform integrates several proprietary technologies including Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based screening platform), Hu-mAtrIx™ (an AI-driven drug discovery platform), and Modalities-on-Demand™ (a next-generation modalities solution), alongside end-to-end preclinical drug development services.